Srt Fabry Galafold denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for srt fabry galafold are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Galafold (Migalastat) for Fabry Disease as Experimental

Aetna's experimental or investigational denial for migalastat (Galafold) typically reflects one of three scenarios: the request is for a patient whose GLA variant has not been confirmed as amenable and therefore falls outside the FDA-approved label; the treating specialty is not aligned with what Aetna considers appropriate for Fabry disease management; or Aetna's clinical policy has not been updated to reflect the current FDA-approved status. For patients with a confirmed amenable GLA variant, migalastat carries full FDA approval and this denial is directly appealable on that basis.

Fabry disease is an X-linked lysosomal storage disorder caused by deficient alpha-galactosidase A activity. Because it is rare, Aetna reviewers may have limited familiarity with the current treatment landscape, making a well-documented appeal with specialist support particularly important.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): File within the deadline on your EOB. Aetna must respond within 30 days for prospective denials or 60 days post-service.
• External review: After an adverse internal decision, request IRO review. For rare-disease cases, explicitly request that the IRO assign a reviewer with relevant specialty expertise. The external-review window is generally up to four months from the final internal denial.
• Expedited track: Available (72 hours) if clinical urgency warrants it.

## Documentation to Gather

1. FDA approval confirmation: The prescriber's appeal letter should explicitly state that migalastat (Galafold) is FDA-approved and identify the approved indication — treatment of adults with a confirmed diagnosis of Fabry disease and an amenable GLA variant. 2. Amenable GLA variant documentation: The genetic testing report identifying the patient's specific GLA variant, paired with confirmation — from the FDA label's amenability criteria or the manufacturer's amenability database — that the variant is amenable. This is the pivotal document. 3. Specialist involvement: Documentation that the treating physician is a specialist in metabolic or lysosomal storage diseases, or a letter from such a specialist supporting the treatment plan. 4. Diagnosis confirmation: Records confirming the Fabry disease diagnosis, including enzyme activity results or genetic testing confirming pathogenic GLA variant. 5. Disease burden documentation: Clinical records documenting the patient's organ involvement, symptom burden, and functional status to establish clinical context. 6. Applicable guideline reference: Reference relevant guidance from appropriate rare-disease or metabolic specialist societies generically.

## Criteria-Mapping Structure

Obtain Aetna's current medical policy for migalastat and list each criterion the policy uses to define "accepted" vs. "experimental" status. For each criterion, provide the specific document that satisfies it — FDA approval letter reference, genetic report, specialist note. Lead with the amenability confirmation and FDA approval status, as these two facts together directly counter the experimental characterization for on-label use.